Connect your AI

Biote Corp. BTMD Change in Deferred Revenue

Change in Deferred Revenue at other companies

NAG

Niagen Bioscience, Inc. Common StockNAGE

-$102K—

Nature's Sunshine ProductsNATR

-$3.1M-956%

Other financials

Income statement

Revenue$44.9M-8.3%

Gross profit$31.0M-14.9%

Operating income$3.2M-67.3%

Net income$2.3M-83.4%

EPS (diluted)$0.06-83.8%

Balance sheet

Cash & equivalents$5.3M-87.2%

Total debt$103.4M-5.5%

Total equity-$56.1M+37.7%

Total assets$89.0M-27.8%

Cash flow

Operating cash flow$3.9M-39.7%

CapEx$362.0K-77.8%

Free cash flow$3.5M-26.8%

Valuation

Market cap$57.33M-51.2%

Enterprise value$155.43M-26.5%

P/E3.7×-0.1×

P/S0.3×-0.3×

Profitability

Gross margin70.1%-1.2pp

Operating margin15.4%-0.1pp

Net margin8.3%-2.3pp

FCF margin15.3%-3.2pp

Returns & leverage

Return on equity-21.4%—

Debt / equity9.1×—

Current ratio1.3×-0.1×

Where this comes from

Reported directly by Biote Corp. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Biote Corp.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biote Corp.'s change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Biote Corp.'s change in deferred revenue?: Biote Corp. (BTMD) reported change in deferred revenue of -$344K in Q1 2026.
How has Biote Corp.'s change in deferred revenue changed year-over-year?: Biote Corp.'s change in deferred revenue decreased by 1128.6% year-over-year, from -$28K to -$344K.
What is the long-term trend for Biote Corp.'s change in deferred revenue?: Over 2 years (2022 to 2025), Biote Corp.'s change in deferred revenue has grown at a 2.1% compound annual growth rate (CAGR), from $384K to -$400K.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.